An amended ownership statement for Keith Murphy, a director of Matinas BioPharma Holdings, Inc. (NYSE:MTNB), was filed on November 9, 2026, to correct the reported exercise price of a stock option granted on November 6, 2026.

Key Highlights

  • Amendment purpose: The filing corrects an administrative error in the exercise price of a stock option previously reported for director Keith Murphy.
  • Corrected exercise price: The stock option exercise price is stated as $1.19 per share in the amended filing.
  • Option grant size: Murphy was granted an option to purchase 5,000 shares of Matinas BioPharma common stock (par value $0.0001 per share).
  • Grant date: The option was granted on November 6, 2026, under the issuer's 2025 Equity Incentive Plan.
  • Vesting terms: The option vests in full on the earlier of the one-year anniversary of the grant date or a "Change in Control" as defined by the Plan, subject to continued service.
  • Expiration date: The option expires on November 6, 2036.
  • Price paid: The price of the derivative security is reported as $0.

Correction to Director Keith Murphy's Option Grant at Matinas BioPharma

According to the filing, the amendment was submitted solely to correct an administrative error in the exercise price of the stock option previously reported in Column 2 of Table II of the original filing dated November 6, 2026. No other aspect of the original filing was changed, the document disclosed. Matinas BioPharma Holdings, Inc. is a biopharmaceutical company whose common stock trades on the NYSE under the ticker MTNB.

The filing states that on November 6, 2026, Murphy was granted an option to purchase 5,000 shares of the issuer's common stock under the company's 2025 Equity Incentive Plan, at a corrected exercise price of $1.19 per share. Following the reported transaction, Murphy beneficially owns 5,000 derivative securities directly, according to the filing. The option was acquired with a transaction code of "A" (acquired), and the filing was signed by Jerome D. Jabbour as attorney-in-fact for Keith Murphy on November 9, 2026.

The vesting schedule, as described in the filing, provides that the option will vest in full upon the earlier of the one-year anniversary of November 6, 2026, or a "Change in Control" as defined by the 2025 Equity Incentive Plan, in each case subject to Murphy's continued service through the applicable vesting date. The option carries an expiration date of November 6, 2036, giving it a ten-year term from the grant date.

What Was Disclosed

Matinas BioPharma director Keith Murphy's amended ownership statement corrected the exercise price of a 5,000-share stock option granted November 6, 2026, to $1.19 per share under the company's 2025 Equity Incentive Plan. No other changes to the original filing were indicated.